Fraxiparine 2850IU AXa/0,3ml

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

nadroparin calcium

Available from:

Aspen Notre Dame de Bondeville

INN (International Name):

nadroparin calcium

Dosage:

2850IU AXa/0,3ml

Pharmaceutical form:

solution for injection

Prescription type:

Prescription

Patient Information leaflet

FRAXIPARINE
™
/FRAXIPARINE FORTE
™
/FRAXODI
™
NADROPARIN
QUALITATIVE AND QUANTITATIVE COMPOSITION
_FRAXIPARINE _ [NADROPARIN CALCIUM SOLUTION FOR INJECTION (9,500
ANTI-XA
IUPH.EUR./ML)]
_PRE-FILLED SYRINGES:_
- 0.2 ml of solution equivalent to 1,900 anti-Xa IU
- 0.3 ml of solution equivalent to 2,850 anti-Xa IU
- 0.4 ml of solution equivalent to 3,800 anti-Xa IU.
_GRADUATED PRE-FILLED SYRINGES:_
- 0.6 ml of solution equivalent to 5,700 anti-Xa IU
- 0.8 ml of solution equivalent to 7,600 anti-Xa IU
- 1 ml of solution equivalent to 9,500 anti-Xa IU.
_MULTI DOSE VIALS:_
- 2 ml of solution equivalent to 19,000 anti-Xa IU
- 5 ml of solution equivalent to 47,500 anti-Xa IU
- 15 ml of solution equivalent to 142,500 anti-Xa IU.
_FRAXIPARINE_ _FORTE_ AND _FRAXODI_ [NADROPARIN CALCIUM DOUBLE
STRENGTH SOLUTION
FOR INJECTION (19,000 ANTI-XA IU PH.EUR./ML)]
_GRADUATED PRE-FILLED SYRINGES:_
- 0.6 ml of solution equivalent to 11,400 anti-Xa IU
- 0.8 ml of solution equivalent to 15,200 anti-Xa IU
- 1 ml of solution equivalent to 19,000 anti-Xa IU.
_MULTI-DOSE VIALS:_
- 5 ml of solution equivalent to 95,000 anti-Xa IU.
- 15 ml of solution equivalent to 285,000 anti-Xa IU.
PHARMACEUTICAL FORM
Solution for injection.
CLINICAL PARTICULARS
INDICATIONS
_FRAXIPARINE [NADROPARIN CALCIUM SOLUTION FOR INJECTION (9,500 ANTI-XA
IU/ML)]_
The prophylaxis of thromboembolic disorders, such as:
- those associated with general or orthopaedic surgery
- those in high risk medical patients (respiratory failure and/or
respiratory
infection and/or cardiac failure), hospitalised in intensive care
unit.
The treatment of thromboembolic disorders.
The prevention of clotting during haemodialysis.
The treatment of unstable angina and non-Q wave myocardial infarction.
_FRAXIPARINE FORTE _AND _FRAXODI_ _[NADROPARIN CALCIUM DOUBLE STRENGTH
SOLUTION _
_FOR INJECTION (19,000 ANTI-XA IU/ML)]_
The treatment of thromboembolic disorders.
DOSAGE AND ADMINISTRATION
Particular attention should be paid to the specific dosing
instructions for each
proprietary Low M

Summary of Product characteristics

1
SUMMARY OF PRODUCT CHARACTERISTICS
FRAXIPARINE™/FRAXIPARINE FORTE™/FRAXODI™
NADROPARIN
QUALITATIVE AND QUANTITATIVE COMPOSITION
_FRAXIPARINE_
_™_
_ _[NADROPARIN CALCIUM SOLUTION FOR INJECTION (9,500 ANTI-XA
IUPH.EUR./ML)]
_ _
_PRE-FILLED SYRINGES: _
-
0.2 ml of solution equivalent to 1,900 anti-Xa IU
-
0.3 ml of solution equivalent to 2,850 anti-Xa IU
-
0.4 ml of solution equivalent to 3,800 anti-Xa IU.
_GRADUATED PRE-FILLED SYRINGES: _
-
0.6 ml of solution equivalent to 5,700 anti-Xa IU
-
0.8 ml of solution equivalent to 7,600 anti-Xa IU
-
1 ml of solution equivalent to 9,500 anti-Xa IU.
_MULTI DOSE VIALS: _
-
2 ml of solution equivalent to 19,000 anti-Xa IU
-
5 ml of solution equivalent to 47,500 anti-Xa IU
-
15 ml of solution equivalent to 142,500 anti-Xa IU.
_FRAXIPARINE FORTE_
_™_ AND _FRAXODI_
_™_ [NADROPARIN CALCIUM DOUBLE STRENGTH
SOLUTION FOR INJECTION (19,000 ANTI-XA IU PH.EUR./ML)]
_GRADUATED PRE-FILLED SYRINGES: _
-
0.6 ml of solution equivalent to 11,400 anti-Xa IU
-
0.8 ml of solution equivalent to 15,200 anti-Xa IU
-
1 ml of solution equivalent to 19,000 anti-Xa IU.
_MULTI-DOSE VIALS: _
-
5 ml of solution equivalent to 95,000 anti-Xa IU.
-
15 ml of solution equivalent to 285,000 anti-Xa IU.
PHARMACEUTICAL FORM
Solution for injection.
2
CLINICAL PARTICULARS
INDICATIONS
_FRAXIPARINE [NADROPARIN CALCIUM SOLUTION FOR INJECTION (9,500 ANTI-XA
IU/ML)] _

The prophylaxis of thromboembolic disorders, such as:
-
those associated with general or orthopaedic surgery
-
those in high risk medical patients (respiratory failure and/or
respiratory infection
and/or cardiac failure), hospitalised in intensive care unit.

The treatment of thromboembolic disorders.

The prevention of clotting during haemodialysis.

The treatment of unstable angina and non-Q wave myocardial infarction.
_FRAXIPARINE FORTE _AND _FRAXODI_ _[NADROPARIN CALCIUM DOUBLE STRENGTH
_
_SOLUTION FOR INJECTION (19,000 ANTI-XA IU/ML)] _

The treatment of thromboembolic disorders.
DOSAGE AND ADMINISTRATION
Particular atte